"Hepatotoxicity Testing based on Adverse Outcome Pathways" - Insphero

“Hepatotoxicity Testing based on Adverse Outcome Pathways”

Jun 23 - 24, 2016


Adverse outcome pathways (AOPs) are novel tools in toxicology and human risk assessment with broad potential. AOPs are designed to provide a clear-cut mechanistic representation of critical toxicological effects that span over different layers of biological organization. AOPs share a common structure consisting of a molecular initiating event, a series of intermediate steps and key events, and an adverse outcome.

Elaborate AOP frameworks have been proposed for chemical-induced skin sensitization, cholestasis, liver fibrosis and liver steatosis. These newly postulated AOPs can serve a number of ubiquitous purposes, including the establishment of (quantitative) structure–activity relationships, the development of novel in vitro toxicity screening tests and the elaboration of prioritization strategies.

Development of AOPs ideally complies with OECD guidelines. There is currently one AOP (34) on “LXR activation leading to hepatic steatosis” that is relevant for the participants as a case-study. The participants will go through the diffferent novel hepatic systems of the liver (and their molecular components) linked to the relevant AOPs at different stages of development.

June 23 – 24, 2016

Biopredic International – Parc d’activité de la Bretèche Bâtiment A4,
Saint Grégoire, France

June 23,
14.30 – 15.30 Lecture: Why 3D cell culture?
by Dr. Katrin Rössger of InSphero

Hands-on Training:
June 23, 16.30 – 18.00 Hands-on-Training: 3D Cell-based assay
by Dr. Katrin Rössger of InSphero

Find out more aobut the CAAT “Hepatotoxicity Testing based on Adverse Outcome Pathways” Training